Increased Medicaid Rebates Will Not Significantly Change Generic Manufacturer Participation, CBO Says
This article was originally published in The Pink Sheet Daily
The overall size of the Medicaid program will spur continued participation, according to the Congressional Budget Office.
You may also be interested in...
The Medicaid reform provision was marked up within budget reconciliation legislation that otherwise remained unchanged.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles